Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review.

Breakthrough pain Cancer pain Rapid-onset opioids

Journal

Journal of Yeungnam medical science
ISSN: 2799-8010
Titre abrégé: J Yeungnam Med Sci
Pays: Korea (South)
ID NLM: 9918333886606676

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 03 04 2023
accepted: 19 05 2023
medline: 10 7 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: aheadofprint

Résumé

Breakthrough pain is transitory pain that occurs despite the use of opioids for background pain control. Breakthrough pain occurs in 40% to 80% of patients with cancer pain. Despite effective analgesic therapy, patients and their caregivers often feel that their pain is not sufficiently controlled. Therefore, an improved understanding of breakthrough pain and its management is essential for all physicians caring for patients with cancer. This article reviews the definition, clinical manifestations, accurate diagnostic strategies, and optimal treatment options for breakthrough pain in patients with cancer. This review focuses on the efficacy and safety of rapid-onset opioids, which are the primary rescue drugs for breakthrough pain.

Identifiants

pubmed: 37424088
pii: jyms.2023.00367
doi: 10.12701/jyms.2023.00367
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Jinseok Yeo (J)

Department of Anesthesiology and Pain Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

Classifications MeSH